Hikal share news, announcements and annual reports
NSE: HIKALBSE: 524735Pharmaceuticals & BiotechnologySmall Cap
Hikal Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1995 on BSE, Feb 2001 on NSE
Last close ₹204.40up ₹2.30 (1.14%)BSE ₹204.75
Share price at the NSE close on 29 Oct 2026. Previous close ₹202.10.
29 Oct: open ₹202.21, high ₹206.02, low ₹201.61
52-week range of traded prices to 29 Oct 2026
₹146.25Low, 30 Mar 2026₹261.00High, 4 Dec 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,520 Cr1,090th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.10
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −2.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹76 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 3.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.57
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,47,46136.8% delivered
Hikal orders, deals and press releases
42 filed, newest first.
Oct 2026
Sep 2026
Aug 2026
Jul 2026
May 2026
Feb 2026
Nov 2025
Aug 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Apr 2024
Feb 2024
Jan 2024
Nov 2023
Sep 2023
May 2023
Feb 2023
Nov 2022
Aug 2022
May 2022
Feb 2022
Oct 2021
Aug 2021
May 2021
Feb 2021
4 Feb · Business
Nov 2020
Aug 2020
Jun 2020
18 Jun · Business
Jun 2017
Feb 2012
4 Feb · Business
Equity shareholders of the Company have unanimously approved the Scheme of Arrangement between Acoris Research Limited and Hikal Limited and their respective Shareholders and Creditors ("Scheme") in their meeting held on February 02, 2012 pursuant to an order dated December 23, 2011 of the Hon'ble High Court of Judicature at Bombay. Further, the members of the company have also approved the utilization of securities premium account in terms of the Scheme in the extraordinary general meeting held on February 02, 2012 after the court convened meeting of the shareholders.
Jul 2009
6 Jul · Business
Honb'le High Court of Judicature at Bombay has approved the Scheme of Arrangement between Hikal Pharmaceuticals Ltd. and Hikal Ltd. and their respective Shareholders vide order dated June 25, 2009, a certified copy of which was made available on June 30, 2009. Further, certified copy of the order of the Hon'ble High Court of Judicature at Bombay sanctioning the Scheme from March 31, 2009 being Appointed Date, has been filed electronically with the Registrar of Companies, Maharashtra, Mumbai on June 30, 2009. Thus, the Scheme has become effective from June 30, 2009, being the date on which the said certified copy of the order sanctioning the Scheme passed by the High Court has been filed with the Registrar of Companies, Maharashtra, Mumbai. Accordingly, Hikal Pharmaceuticals Limited has been amalgamated with Hikal Limited and stands dissolved without being wound up
Mar 2009
26 Mar · Business
Board of Directors of the Company at there meeting held on March 25, 2009 considered and approved a Scheme of Arrangement which provides for merger of Hikal Pharmaceuticals Limited ('Hikal Pharm'), a wholly owned subsidiary of the Company with itself. The Appointed Date of the Scheme of Arrangement is March 25, 2009 i.e. the date of Board meeting approving the Scheme of Arrangement. The entire Equity Share Capital of Hikal Pharma is held by the Company and its nominees. Therefore, upon the Scheme becoming effective the entire equity share capital of Hikal Pharma will stand automatically cancelled and there will be no issue and allotment of shares pursuant to the Scheme.The Scheme of Amalgamation is, inter-alia, subject to the necessary approvals under the Companies Act, 1956 including the High Court of Bombay, or any other competent authority.
Jul 2008
4 Jul · Business
Board of Directors at their meeting held on July 03, 2008 has subject to necessary approvals and applicable provisions of law, decided to issue upto 13,60,000 Equity shares of Rs.10/- each on preferential basis to International Finance Corporation (IFC) by investing upto Rs.64.46 crores, in compliance with Chapter XIII of SEBI (Disclosure and Investor Proctection) Guidelines 2000 and Companies Act, 1956.